News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
Harold J. Burstein/X
Jun 3, 2025, 09:15

Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

Harold J. Burstein, Breast Cancer Specialist and Professor at Harvard Medical School, posted on X:

“The NEJM has published SERENA-6 data ahead of ASCO25 plenary.
Cami joins other SERDS (elacestrant, imlunestrant, vepdegestrant) with activity in ESR1mut BC
Key questions to think about ahead of session:
1. Intensive ctDNA screening of 10 patients to find 1 who might qualify for ‘switching’ based on ESR1mut. Worthwhile?
2. Does switching among asymptomatic patients with no radiological progression make sense when drug could be added later at progression?
3. Is this fundamentally different than switching treatment based on small upticks in serum tumor markers, without overt progression?
4. Adds to data from EMBER-3 that SERD + CDK46i looks to be effective. Is 2nd line CDK46i now the standard?”

Title: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

Authors: François-Clément Bidard, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Peter A. Fasching, Adam Brufsky, Zbigniew Nowecki, Javier Pascual, Lionel Moreau, Shin-Cheh Chen, Nuri Karadurmus, Einav Nili Gal-Yam, Kyung Hae Jung, Sonia Pernas, Sasha McClain, Wei He, Teresa Klinowska, Cynthia Huang-Bartlett, Nicholas C. Turner

Read The Full Article at NEJM.

Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

More posts featuring ASCO25.

Adam Brufsky cancer Cynthia Huang-Bartlett Cynthia Ma Einav Nili Gal-Yam Erica L. Mayer François-Clément Bidard Giampaolo Bianchini Harold J. Burstein Hiroji Iwata Javier Pascual Kevin Kalinsky Kyung Hae Jung Lionel Moreau Massimo Cristofanilli Nicholas C. Turner Nuri Karadurmus OncoDaily Oncology Peter A. Fasching Sasha McClain Shin-Cheh Chen Sonia Pernas. Stephen Chia Teresa Klinowska Wei He Wolfgang Janni Yeon Hee Park Zbigniew Nowecki
Special Coverage
Career
Jun 4, 2025, 17:30
Fellowship and Short-Term Training Opportunities Now Open at POEM Training Centers - POEM Group
Celebrities
Jun 4, 2025, 17:16
Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?
Blog
Jun 4, 2025, 17:13
Katy Rezvani Has Been Appointed as AACR 2026 Program Committee Co-Chair and Elected to the Association of American Physicians
Blog
Jun 4, 2025, 17:07
Teresa Amaral: The Fantastic Faculty of The ASCO and ESMO Session at ASCO25 Congress
Blog
Jun 4, 2025, 17:02
Jennifer Buell Highlights Strategic Partnership Between Agenus and Zydus
Blog
Jun 4, 2025, 16:52
Olubukola Ayodele: I Leave ASCO25 Feeling Recharged Not Just By Data But By Direction
Insight
Jun 4, 2025, 16:33
Paolo Tarantino on Sara Tolaney’s Leadership and Mentorship at ASCO 2025
Blog
Jun 4, 2025, 16:33
Maryam Lustberg: Grateful For My MASCC Family
Insight
Jun 4, 2025, 16:30
Jasmine Kamboj Celebrated ASCO Advocacy Award with Team Minnesota at ASCO 2025
Blog
Jun 4, 2025, 16:27
Hadieh Eslampanah: Happy International Cancer Survivors Day 2025 - New Life and New Beginning
Oncolibrary
Jun 4, 2025, 16:20
IMMUNOSARC II Study Results: Sunitinib Plus Nivolumab Shows Promising Activity in Advanced Extraskeletal Myxoid Chondrosarcoma (EMC)
Blog
Jun 4, 2025, 15:56
SIOG Announces Interactive Geriatric Assessment Workshop for SIOG 2025